# Alkermes plc Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/ALKS/alkermes-plc-reports-first-quarter-2026-financial-results
Ticker: ALKS
Company: Alkermes plc
Source: Alkermes plc
Published: 2026-05-05 11:00 EST
Original Source URL: https://investor.alkermes.com
## Summary

DUBLIN --(BUSINESS WIRE)--May 5, 2026-- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 earnings press release and presentation, please visit the company’s

## Article Body
DUBLIN --(BUSINESS WIRE)--May 5, 2026-- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 earnings press release and presentation, please visit the company’s
## Recent Company News
- 2026-06-04 11:00 EST — [Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research](https://biopharmsignal.com/news/ALKS/alkermes-to-present-new-data-on-alixorexton-and-lumryzr-sodium-oxybate-at-sleep-2026-highlighting-breadth-of-sleep-medicine-research) — Source: Alkermes plc
- 2026-06-03 20:05 EST — [Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/ALKS/alkermes-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Alkermes plc
- 2026-05-26 11:00 EST — [Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting](https://biopharmsignal.com/news/ALKS/alkermes-to-showcase-leadership-in-psychiatry-and-orexin-biology-with-new-data-at-the-american-society-of-clinical-psychopharmacology-annual-meeting) — Source: Alkermes plc
- 2026-05-21 11:00 EST — [Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences](https://biopharmsignal.com/news/ALKS/alkermes-showcases-data-from-psychiatry-portfolio-and-sleep-research-into-real-world-patient-experience-at-spring-2026-scientific-conferences) — Source: Alkermes plc
- 2026-05-12 11:00 EST — [Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia](https://biopharmsignal.com/news/ALKS/alkermes-announces-positive-topline-results-from-revitalyz-phase-3-study-evaluating-lumryzr-sodium-oxybate-extended-release-in-adults-with-idiopathic-hypersomnia) — Source: Alkermes plc
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)